Compare MTEK & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MTEK | EDSA |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | Israel | Canada |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.1M | 12.8M |
| IPO Year | 2022 | N/A |
| Metric | MTEK | EDSA |
|---|---|---|
| Price | $1.36 | $1.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | ★ 68.7K | 28.1K |
| Earning Date | 09-26-2025 | 12-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,375,716.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.03 | $1.55 |
| 52 Week High | $6.47 | $4.49 |
| Indicator | MTEK | EDSA |
|---|---|---|
| Relative Strength Index (RSI) | 44.72 | 42.59 |
| Support Level | $1.34 | $1.71 |
| Resistance Level | $1.54 | $1.82 |
| Average True Range (ATR) | 0.09 | 0.07 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 50.32 | 43.75 |
Maris Tech Ltd is a business-to-business approach, or B2B provider of remote video, audio, telemetry acquisition, distribution, and sharing solutions and products, using high-end digital video, audio, and wireless communication technologies. It designs, develops, manufactures and commercially sells miniature intelligent video and audio surveillance and communication systems, which are offered as products and solutions for the professional as well as the civilian and home security markets.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.